Introduction The use of flow diversion devices to treat intracranial aneurysms has recently increased.

Aim of Study Assess the safety and efficacy of the pEGASUS (HPC) FD device.

Methods Between May 2022 and May 2023, we retrospectively identified all patients treated with pEGASUS (HPC) FD at our center. Aneurysms located in the anterior and posterior circulation were included, as well as previously treated aneurysms; no previous parent vessel stent-treated aneurysm were included. All patients underwent a combination of coiling and FD treatment. Imaging FU included a MR-angiography (MRA) at 2 days and at 3–6 months after treatment. Our primary safety endpoint was the incidence of complications and mortality at follow-up, with the primary efficacy endpoint being complete aneurysm occlusion on follow-up.

Results 15 patients underwent treatment, the mean aneurysm dome width was 6.7±1.5 mm and neck width 4.9±1.4 mm. Adjunctive coiling was performed in all patients with jailing technique (42.8%), direct crossing of the FD (28.6%) and subsequent FD deployment after coiling (28.6%). There were no intraprocedural complications and on 3-months MRA FU a complete aneurysm occlusion (mRROC 1) was seen in 22.3%, a mRROC 2 in 66.7%, and a mRROC 3a/b in 11.0%. In our series at 3 moths FU the mortality rate was 0%.

Conclusion In our small case series, the pEGASUS (HPC) FDs appears as an effective and safe device for intracranial aneurysm’ treatment, with a high aneurysm occlusion rate with a single device and a low mortality rate at 3-months FU. Long-term FU data are pending.

Disclosure of Interest I have nothing to disclose